Elemer Piros on the Potential of Psychedelics

Elemer Piros, Managing Director & Senior Research Analyst at Roth Capital Markets, speaks about the expanding psychedelics market. …

Elemer Piros

Elemer Piros, Managing Director & Senior Research Analyst at Roth Capital Markets, speaks about the expanding psychedelics market.

According to Piros, psychedelic clinic research is in an explosive phase. They are seeing confirmation of previous academic work, but this time done properly, with controls.

"The potential is there to actually revolutionize mental health care - depression, PTSD, anxiety, eating disorders and substance abuse," says Piros. The remission rates are double to triple in comparison to placebo or standard of care. "These kinds of results are unheard of in the history of mental health care."

No items found.

You might also like

Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs
Life Sciences
August 28, 2026

Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs

Next-generation weight-management drugs face a simple challenge: effectiveness must be matched by tolerability.

This is some text inside of a div block.
Brompton LCS: How Can Investors Earn Monthly Income from Canadian Life Insurers?
Finance
August 27, 2026

Brompton LCS: How Can Investors Earn Monthly Income from Canadian Life Insurers?

This is some text inside of a div block.
Brompton Funds
ETFs
August 27, 2026

Brompton Funds: Enhanced Multi-Asset Income ETF - BMAX

BMAX is designed to provide attractive monthly distributions and the opportunity for capital appreciation by investing in a portfolio of Brompton ETFs and preferred shares.

This is some text inside of a div block.
Subscribe and receive the investor Info